Uncategorized

ITM neuroendocrine tumor drug spurned by FDA over manufacturing qualms

Published

on

The FDA has denied ITM Isotopes Technologies’ lead pipeline candidate for a rare group of tumors due to qualms over the drug’s manufacturing.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version